


# Breast cancer treatment from thiazolidinedione derivatives

cancer / triple-negative breast cancer / troglitazone / anticancer drug / oncology



## CONTEXT

Treatments against breast cancer occur certain limits: innate or acquired resistance, absence of targeted therapy for certain tumors.

Although the anticancer properties of thiazolidinediones have been demonstrated *in vitro* and *in vivo* (phase II clinical study), some of them cannot be used due to excessive hepatotoxicity.

## DESCRIPTION

The invention consists in the development of a very stable troglitazone derivative, 4 times less toxic on primary hepatocyte culture (80% viability vs. 23%) and whose *in vitro* antiproliferative activity is 10 times higher than troglitazone.

*In vivo* preclinical tests on xenografted mice are ongoing.

## COMPETITIVE ADVANTAGES

- Increased efficacy against breast cancers even resistant to treatments and triple-negative cancers for which there is no targeted therapy
- Reduced side effects: 70% less liver toxicity compared to troglitazone



## Markets & applications

Pharmaceutical:

- ❖ Anti-cancer treatment



## Development stage

TRL 4: *in vitro* toxicity and anticancer activity validation



## Intellectual property

Patent registered in France on January 26th, 2012 (FR2986231) and extended in Europe (October 2016 ; EP2838899) and USA (December 2016 ; US2014364465)



## Target partnership

Patent licensing

## CONTACT-US

**Daniel KIRCHHERR**

Business Development Manager

+33 (0)7 76 16 66 90

daniel.kirchherr@sayens.fr